Procept BioRobotics Corporation (PRCT) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Procept BioRobotics Corporation (PRCT:NASDAQ), powered by AI.

Current Price
$25.70
P/E Ratio
-14.9
Market Cap
1.4B
Sector
Healthcare
What is the Procept BioRobotics Corporation stock price forecast?

Procept BioRobotics Corporation is currently trading at $25.70. View real-time AI analysis on Alpha Lenz.

What is Procept BioRobotics Corporation insider trading activity?

View the latest insider trading data for Procept BioRobotics Corporation on Alpha Lenz.

What is Procept BioRobotics Corporation's P/E ratio?

Procept BioRobotics Corporation's P/E ratio is -14.9.

Procept BioRobotics Corporation

NASDAQ · PRCT
$25.70-1.99(-7.17%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Procept BioRobotics Corporation's future dividend policy...
Alpha Chat Insight

Procept BioRobotics Corporation trades at a P/E of -14.9 (undervalued) with modest ROE of -24.9%. 3Y revenue CAGR of 60.1% highlights clear growth momentum.

Ask for details

Company Overview

Procept BioRobotics Corporation focuses on developing and commercializing surgical robotics technology. The company's flagship product, AquaBeam Robotic System, is designed to treat lower urinary tract symptoms caused by benign prostatic hyperplasia, a condition commonly affecting older men. Utilizing advanced imaging, the robotic system provides a minimally invasive treatment option that improves patient outcomes by reducing recovery times and hospital stays. Procept BioRobotics serves a critical role in the medical device industry, emphasizing innovation in surgical solutions for urological health. As a pioneer in autonomous tissue resection, Procept BioRobotics aims to enhance the efficiency and safety of surgical procedures, making it an influential player in the field of medical robotics. Based in the healthcare sector, the company's technologies are increasingly significant as the demand for precision medicine and minimally invasive procedures grows. Procept BioRobotics is strategically positioned at the intersection of technological advancement and healthcare improvement, contributing to the ongoing evolution of medical treatment methodologies.

CEOMr. Larry L. Wood
SectorHealthcare
IndustryMedical Devices
Employees756

Company Statistics

FY 2025

Profile

$1.43BMarket Cap
$308.05MRevenue
0.00Shares Out
756Employees

Margins

63.70%Gross
-27.72%EBITDA
-33.71%Operating
-30.96%Pre-Tax
-31.02%Net

Valuation

-14.94P/E
3.90P/B
4.63EV/Sales
-14.28EV/EBITDA
-24.47P/FCF

Growth (CAGR)

60.14%Rev 3Yr
109.04%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-18.34%ROA
-24.89%ROE
-17.62%ROIC

Financial Health

$286.50MCash & Cash Equivalents
$-144.29MNet Debt
38.87%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Procept BioRobotics Corporation (ticker: PRCT) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 756 employees. Market cap is $1.4B.

The current price is $25.705 with a P/E ratio of -14.94x and P/B of 3.9x.

ROE is -24.89% and operating margin is -33.71%. Annual revenue is $308M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Procept BioRobotics Corporation (PRCT) Stock Forecast 2026 $25.70 — Price, Financials & Analyst Targets | Alpha Lenz